glp 1 based therapies Application of nutrition interventions with GLP-1 therapies: A narrative review of the challenges and solutions JCI - Antiinflammatory actions of

physiology 8, 1045

It is the first triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, a mechanism that produced 24.2% mean body weight reduction in Phase 2 trials and a staggering 28.7% in Phase 3 data

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or any other anti-diabetic drug

Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program

The figure of 20 million users globally may not accurately represent the number of individuals who could benefit from GLP-1 drugs, as there may be barriers to access such as cost, healthcare infrastructure, and awareness